Table 1.
CIDP patients harbouring anti-ganglioside antibodies.
| Patient ID | Results |
|---|---|
| 7 | sulfatides IgM 1/31356 |
| sulfatides IgG 1/832 | |
| 22 | IgM aGM1 1/500 |
| 24 | sulfatides IgM 1/592 |
| 31 | IgG GM1 1/6160 |
| IgM GM1 1/2314 | |
| IgM aGM1 1/1442 | |
| IgM GD1b1/500 | |
| 32 | IgG aGM1 1/580 |
| 36 | IgM GM1 1/2154 |
| 39 | IgG aGM1 1/528 |
| IgG GD1a 1/528 | |
| IgM aGM1 1/2559 | |
| sulfatides IgM 1/3245 | |
| sulfatides IgG 1/831 | |
| 55 | sulfatides IgM 1/800 |
| IgM aGM1 1/500 | |
| 56 | IgG aGM1 1/1000 |
| IgM GM1 1/500 | |
| 64 | IgM GM1 > 1/12500 |
| IgM aGM1 > 1/12500 | |
| IgM GD1b > 1/12500 | |
| 65 | IgM GM1 1/7829 |
| IgM aGM1 1/2359 | |
| IgM GD1b 1/2868 |
Fifty-nine patients were screened using our institution’s anti-ganglioside ELISA diagnostic technique, further confirmed by TLC.